Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study

BACKGROUND: Crizotinib was the first oral targeted therapy approved by the US Food and Drug Administration (FDA), on 11 March 2016, for c-ros oncogene 1 (ROS1)-positive advanced non-small-cell lung cancer (NSCLC). Data to support long-term clinical benefit in a real-world setting are limited. OBJECT...

Descripción completa

Detalles Bibliográficos
Autores principales: Waterhouse, David, Iadeluca, Laura, Sura, Sneha, Wilner, Keith, Emir, Birol, Krulewicz, Stan, Espirito, Janet, Bartolome, Lauren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783880/
https://www.ncbi.nlm.nih.gov/pubmed/34964940
http://dx.doi.org/10.1007/s11523-021-00860-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783880/
https://www.ncbi.nlm.nih.gov/pubmed/34964940
http://dx.doi.org/10.1007/s11523-021-00860-z

Ejemplares similares